Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 12, 2024 2:00 PM ET Company Participants Jennifer Taubert - Executive Vice President, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's get started.
Cancer victims ask court to block J&J talc bankruptcy
A group of cancer victims asked a federal judge to block Johnson & Johnson's proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's baby powder and other talc products caused their illnesses, according to a court filing.
Johnson & Johnson to pay $700 million settlement over talc products linked to cancer
Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for allegedly causing cancer.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
Artificial intelligence is forecast to drive an innovation bonanza in healthcare. This innovation boom is expected to increase the human lifespan dramatically.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $146.76, moving -0.25% from the previous trading session.
7 Recession-Proof Stocks to Buy Now for Peace of Mind
Maintaining stability and security in investment portfolios is vital in an adverse macroeconomic environment. For instance, the current higher-for-longer interest rate environment coupled with other volatile macro elements may lead stocks into an unexpected and sudden downfall.
Johnson & Johnson reaches $700 million talc settlement with US states
Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other products that contained talc.
J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut
Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.
J&J-backed Rapport Therapeutics raises $136 mln in US IPO
Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
Johnson & Johnson (JNJ) closed at $145.97 in the latest trading session, marking a -1.24% move from the prior day.
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.
